T and B cell responses following primary COVID-19 vaccination with CoronaVac and two heterologous BNT162b2 booster doses
mSphere · 2025
DOI: 10.1128/msphere.00722-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift mSphere, 2025. Verfasst von Apirath Wangteeraprasert und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology, Department of Internal Medicine, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand. Hauptthemen laut MEDLINE: Immunization, Secondary, COVID-19, SARS-CoV-2, COVID-19 Vaccines. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMHD NIH HHS, Naresuan University, Thailand Science Research and Innovation.
Abstract (Originalsprache)
The present study investigated T and B cell responses following a second heterologous booster dose of BNT162b2 administered after a two-dose CoronaVac regimen for coronavirus disease 2019 (COVID-19) vaccination in 15 healthcare workers. Blood samples were collected 4 weeks after the first booster and at both 4 and 24 weeks after the second BNT162b2 booster. Interferon-γ-secreting CD4+ and CD8+ T cells were detectable 4 weeks after the first booster, whereas only CD4+ T cells remained detectable at both 4 and 24 weeks after the second booster. Seven of the 15 participants (46.7%) were diagnosed with COVID-19 approximately 16 weeks after receiving the second booster. These individuals exhibited significantly higher frequencies of CD4+ T cells at 24 weeks post-booster than at 4 weeks post-booster. In contrast, the non-COVID-19 group exhibited significantly higher CD4+ T cell responses 4 weeks after the second booster. Memory B cells were detected at low frequencies at all three time points. IgG antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein were detectable at all three time points, with a significant decline observed 24 weeks after the second booster. Overall, CD4+ T and B cell responses induced by a heterologous second booster dose of BNT162b2 following a primary two-dose CoronaVac regimen were rapidly elicited and sustained for at least 6 months. IMPORTANCE There is limited evidence regarding T and B cell responses following a primary COVID-19 vaccination series with CoronaVac and two heterologous BNT162b2 booster doses. This study investigated the longitudinal T and B cell responses induced by a second heterologous BNT162b2 booster following a primary two-dose CoronaVac COVID-19 vaccination regimen. These results demonstrate that CD4+ T cells induced by the second heterologous BNT162b2 booster play a key role in protection against SARS-CoV-2 infection and progression to severe disease. This study suggests the need for the future consideration of repeated emergency vaccine-boosting strategies in response to emerging viral infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Immunology, Department of Internal Medicine, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand.
- Department of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand.
- Division of Pulmonology, Department of Internal Medicine, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand.
ORCID-Profile: Supawadee Makanut
Förderung
- NIMHD NIH HHS
- Naresuan University
- Thailand Science Research and Innovation
Zitieren
APA
Wangteeraprasert, A., Pongcharoen, S., Ngoenkam, J., & Makanut, S. (2025). T and B cell responses following primary COVID-19 vaccination with CoronaVac and two heterologous BNT162b2 booster doses. mSphere. https://doi.org/10.1128/msphere.00722-25
Vancouver
Wangteeraprasert A, Pongcharoen S, Ngoenkam J, Makanut S. T and B cell responses following primary COVID-19 vaccination with CoronaVac and two heterologous BNT162b2 booster doses. mSphere. 2025. doi:10.1128/msphere.00722-25
BibTeX
@article{Wangteeraprasert2025,
author = {Wangteeraprasert, Apirath and Pongcharoen, Sutatip and Ngoenkam, Jatuporn and Makanut, Supawadee},
title = {T and B cell responses following primary COVID-19 vaccination with CoronaVac and two heterologous BNT162b2 booster doses},
journal = {mSphere},
year = {2025},
doi = {10.1128/msphere.00722-25}
}
EUVIMED